Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review of randomized trials.

[1]  P. Bekker,et al.  Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial , 2020, JMIR research protocols.

[2]  R. B. Henderson,et al.  Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study , 2019, Arthritis & rheumatology.

[3]  P. Ravaud,et al.  Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis. , 2019, Clinical and experimental rheumatology.

[4]  P. Tugwell,et al.  Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health , 2019, The Journal of Rheumatology.

[5]  V. Tesar,et al.  Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial , 2019, Annals of the rheumatic diseases.

[6]  J. McGowan,et al.  PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation , 2018, Annals of Internal Medicine.

[7]  S. Jowett,et al.  Treatment of fatigue with physical activity and behavioural change support in vasculitis: study protocol for an open-label randomised controlled feasibility study , 2018, BMJ Open.

[8]  P. Merkel,et al.  Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire , 2018, Annals of the rheumatic diseases.

[9]  P. Ravaud,et al.  Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2) , 2018, Annals of the rheumatic diseases.

[10]  T. Sugiyama,et al.  Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial , 2017, BMJ Open.

[11]  S. Andrulli,et al.  Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial , 2017, PloS one.

[12]  P. Tugwell,et al.  OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis , 2017, The Journal of Rheumatology.

[13]  M. Jadoul,et al.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. , 2017, Journal of the American Society of Nephrology : JASN.

[14]  G. Baron,et al.  Adding Azathioprine to Remission‐Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors , 2017, Arthritis & rheumatology.

[15]  M. Haubitz,et al.  Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis , 2017, Annals of the rheumatic diseases.

[16]  P. Merkel,et al.  Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial , 2017, Trials.

[17]  P. Tugwell,et al.  Clinicians’ perspective on key domains in ANCA-associated vasculitis: a Delphi exercise , 2017, Scandinavian journal of rheumatology.

[18]  C. Kallenberg,et al.  Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  P. Ravaud,et al.  Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty‐Five Years or Older: Results of a Multicenter, Open‐Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide–Based Induction Therapy , 2015, Arthritis & rheumatology.

[20]  P. Ravaud,et al.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.

[21]  P. Tugwell,et al.  Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. , 2014, Journal of clinical epidemiology.

[22]  P. Merkel,et al.  Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's) , 2014, Arthritis & rheumatology.

[23]  P. Merkel,et al.  Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial , 2013, Trials.

[24]  J. Smolen,et al.  Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions , 2012, Annals of the rheumatic diseases.

[25]  M. Mitobe,et al.  Estimation of BVAS in patients with microscopic polyangiitis in Japan , 2011, Clinical Rheumatology.

[26]  P. Merkel,et al.  The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis , 2011, The Journal of Rheumatology.

[27]  Qiang He,et al.  Effects of Mycophenolate Mofetil Combined with Corticosteroids for Induction Therapy of Microscopic Polyangiitis , 2011, American Journal of Nephrology.

[28]  V. Tesar,et al.  Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. , 2010, JAMA.

[29]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[30]  P. van Paassen,et al.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. , 2010, The New England journal of medicine.

[31]  C. Ribi,et al.  Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. , 2010, Arthritis and rheumatism.

[32]  W. Lukas,et al.  Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement , 2009, European journal of medical research.

[33]  V. Tesar,et al.  Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic AntibodyAssociated Vasculitis , 2009, Annals of Internal Medicine.

[34]  L. Mouthon,et al.  Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. , 2008, The New England journal of medicine.

[35]  J. Krischer,et al.  Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis , 2008, Annals of the rheumatic diseases.

[36]  D. Abramowicz,et al.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. , 2007, Journal of the American Society of Nephrology : JASN.

[37]  K. De Groot,et al.  Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. , 2007, Rheumatology.

[38]  Zhihong Liu,et al.  Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  H. Raspe,et al.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis , 2006, Annals of the rheumatic diseases.

[40]  C. Feighery,et al.  Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. , 2005, Arthritis and rheumatism.

[41]  V. Tesar,et al.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. , 2003, The New England journal of medicine.

[42]  L. Mouthon,et al.  Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. , 2003, Arthritis and rheumatism.

[43]  P. Merkel,et al.  A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). , 2001, Arthritis and rheumatism.

[44]  D. Adu,et al.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. , 2000, QJM : monthly journal of the Association of Physicians.

[45]  M. Haubitz,et al.  Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. , 1998, Arthritis and rheumatism.

[46]  B. Hoen,et al.  A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. , 1997, Arthritis and rheumatism.

[47]  D. Adu,et al.  Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. , 1997, QJM : monthly journal of the Association of Physicians.

[48]  G. Kitas,et al.  Disease assessment and management of the vasculitides. , 1997, Bailliere's clinical rheumatology.

[49]  C. Gordon,et al.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.

[50]  C. Kallenberg,et al.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis , 1996 .

[51]  R. Moots,et al.  VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis. , 1995, Clinical and experimental rheumatology.

[52]  R. Moots,et al.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.

[53]  C. Sherbourne,et al.  The MOS 36-ltem Short-Form Health Survey (SF-36): III. Tests of Data Quality, Scaling Assumptions, and Reliability Across Diverse Patient Groups , 1994, Medical care.

[54]  T. The,et al.  Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre , 1990, The Lancet.

[55]  M. Nisar.  Crystallising the role of adrenocorticotrophic hormone in the management of acute gout: a review. , 2019, Clinical and experimental rheumatology.

[56]  L. Mouthon,et al.  Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. , 2011, Clinical and experimental rheumatology.

[57]  J. Heaf,et al.  Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[58]  J. Stone.  Etanercept plus Standard Therapy for Wegener's Granulomatosis , 2005 .